Foundayo vs Mounjaro: How the Pill and the Injection Compare

• A clear comparison of a daily tablet against a weekly injection, on the points that affect daily life
• Explains what the MHRA has approved Foundayo for, and what that does not yet tell us
• Honest about why a direct head to head comparison of results does not exist
• Online consultation with UK registered prescribers to find out which route suits you

Foundayo and Mounjaro are both prescription medicines used for weight management, but they are taken differently. Foundayo is a once-daily tablet, while Mounjaro is given as a once-weekly injection. That difference can affect practical issues such as daily routine, storage, travel and how missed doses are managed.

Foundayo contains orforglipron. The MHRA authorised it in the UK on 10 August 2026 for weight management and weight maintenance in eligible adults, alongside a reduced-calorie diet and increased physical activity. It is also authorised to improve blood sugar control in adults with insufficiently controlled type 2 diabetes.

Key things to know

• Foundayo is a once daily tablet containing orforglipron, approved by the MHRA in August 2026.
• Mounjaro is a once weekly injection, and has been licensed for weight management in the UK for longer.
• Foundayo can be taken at any time of day, with no food or water restrictions
• In a phase 3 trial, average weight loss with orforglipron over 72 weeks ranged from around 7.5% to 11.2% depending on the dose studied, against around 2.1% with placebo.
• No published head to head trial compares Foundayo directly against Mounjaro, so results cannot be lined up side by side reliably.
• Both are prescription only medicines and both require a clinical assessment against eligibility criteria.
• Both are incretin-based medicines, but they do not have the same mechanism: orforglipron acts on the GLP-1 receptor, while tirzepatide acts on both GIP and GLP-1 receptors.

Foundayo vs Mounjaro: the short answer

They are different treatments in the same broad family, delivered in different ways, with different amounts of real world experience behind them.

Neither is a lighter or heavier version of the other. They are separate medicines with separate licences, separate evidence and separate side effect profiles, and the choice between them is made on your clinical picture rather than on a ranking.

What is Foundayo?

Foundayo is the brand name for orforglipron, a prescription medicine taken as a once daily tablet. It belongs to the GLP-1 receptor agonist family, meaning it acts on the receptor for glucagon like peptide 1, a hormone involved in appetite regulation, how quickly the stomach empties and how the body handles blood sugar.

What distinguishes Foundayo is its oral formulation and its administration instructions: it is taken once daily and can be taken without food or water restrictions. The MHRA statement on approval describes a tablet taken once daily that can be taken at any time of day, with no food or water restrictions.

What the MHRA has approved it for

The approval covers two separate uses:

1. Weight loss and weight maintenance in adults with a BMI of 30 or more, or a BMI between 27 and 30 where there are weight related health conditions, alongside a reduced calorie diet and increased physical activity
2. Improving blood sugar control in adults with type 2 diabetes where control is inadequate

Those criteria matter because they define who can be considered. Meeting a BMI threshold is a starting point rather than an automatic qualification, since eligibility also depends on your medical history, other conditions and current medicines. Treatment suitability depends on an individual clinical assessment.

The regulator has also said it will keep the safety and effectiveness of orforglipron under close review, which is standard for a newly approved medicine and worth understanding rather than worrying about. It means real world data continues to be collected after approval.

What Mounjaro is, for comparison

Mounjaro is a prescription weight management treatment given as a once weekly injection using a pre-filled device. It acts on two hormone pathways rather than one, which is the main pharmacological difference from a treatment acting on the GLP-1 receptor alone.

Mounjaro has been licensed in the UK for weight management for longer than Foundayo, which matters in a way that is easy to overlook. That means there is more accumulated prescribing experience with tirzepatide in the UK. However, a longer track record should not be interpreted as evidence that one medicine is more effective than the other.

Pill versus injection: the practical differences

For many people the decision is driven less by pharmacology than by what fits their life. These are the differences that show up day to day.

Why the daily versus weekly choice cuts both ways

People often assume weekly is easier because there is less to do. In practice it splits. Those who already take daily medication find a tablet slots into an existing routine without adding anything new, and a missed day matters less. Those who dislike daily medication, or who travel unpredictably, often prefer a single weekly action they can plan around.

There is also a psychological dimension worth naming. Some people find a weekly injection a useful marker, a scheduled point that reinforces the commitment. Others find that same weekly event a source of dread. Neither reaction is wrong, and it is a legitimate thing to raise at an assessment rather than something to keep to yourself.

If you miss a dose, follow the missed-dose instructions in the patient information leaflet for your specific medicine. Do not take extra doses unless your prescriber specifically tells you to.

What the evidence shows

In a phase 3 clinical trial of orforglipron, average weight loss over 72 weeks ranged from around 7.5% to 11.2% of starting body weight depending on the dose studied, compared with around 2.1% for placebo. A separate study reported in early 2026 compared it against an oral weight loss medication in the same family for people with type 2 diabetes.These figures came from a specific clinical trial population and should not be interpreted as a guaranteed result for an individual patient.

Two things about those figures deserve emphasis. They are averages, and individual results sit both above and below them. Results vary between individuals and depend on following a diet and exercise plan alongside medication. These results come from trial conditions, where participants receive structured support alongside the medicine, which is part of why the diet and activity component appears in the licence rather than as an optional extra.

Why you cannot line the two up side by side

There is no published head to head trial comparing Foundayo directly against Mounjaro for weight management. That means any comparison of their weight loss percentages is a cross trial comparison, and those are unreliable for reasons that have nothing to do with the medicines.

Different trials enrol different people, with different starting weights, different health profiles, different levels of support, different durations and different definitions of success. A percentage from one trial and a percentage from another are not measuring the same thing under the same conditions, even when they look directly comparable.

This is the point comparison articles routinely get wrong, and it is worth holding onto: until a direct comparison exists, the honest position is that both are effective treatments with different evidence bases, and the choice is made on suitability rather than on which figure is larger.

Side effects

Both treatments act on similar biological pathways, so the pattern of side effects overlaps substantially. Digestive effects are the ones reported more than any others across this family of medicines, and Foundayo can cause nausea, diarrhoea, and abdominal pain.

Across the placebo-controlled weight-management phase 3 studies, 3.7% to 6.8% of people receiving orforglipron discontinued treatment because of gastrointestinal adverse reactions, compared with 0.6% of those receiving placebo.

Gastrointestinal side effects with Mounjaro may worsen after a dose increase, including nausea and stomach pain.

Less common but more serious effects are described in the patient information leaflet for each product, including pancreatitis and gallbladder problems, and those leaflets list the specific symptoms that mean stopping and seeking urgent advice. Read the leaflet for the treatment you are actually given rather than relying on a general article.

Report suspected side effects from any medicine through the Yellow Card scheme. Reporting matters more than usual with a newly approved medicine, because that is how the safety picture continues to build after approval.

What to raise before starting either

• Your full medical history, including any digestive, pancreatic or gallbladder conditions
• Every medicine you take, including anything bought without a prescription and supplements
• Mention any other oral medications to your prescriber too, as timing and possible interactions still need reviewing even if a tablet is flexible to take
• Any history of thyroid conditions or relevant family history
• Whether you are pregnant, planning pregnancy or breastfeeding
• Any previous experience with treatments in this family, including side effects
• Any current or previous eating disorder or significant concerns about eating behaviour
• After starting treatment, seek medical advice promptly if you develop concerning symptoms or if side effects become difficult to manage

Who each one may suit

Neither is a default. The considerations below are the ones a prescriber weighs, and they are worth thinking about before an assessment so the conversation is more productive.

Your prescriber will determine the appropriate treatment, based partly on your weight management goals as well as your wider medical picture. This medicine should only be used under the supervision of an appropriately qualified prescriber.

Foundayo availability in the UK

The MHRA authorised Foundayo (orforglipron) in the UK on 10 August 2026 for weight management and for improving glycaemic control in adults with insufficiently controlled type 2 diabetes.

Since regulatory approval and commercial supply are separate stages, availability can change as pharmacies and private prescribing services begin supplying a newly authorised medicine. Current UK listings show Foundayo being supplied through private prescription services, although availability, pricing and stock can vary between providers.

Foundayo is prescription-only. The UK product information specifies a starting dose of 0.8 mg once daily, with dose increases made at intervals of at least 30 days according to treatment response and tolerability. The maximum daily dose is 17.2 mg.

A prescriber should assess whether treatment is appropriate, review other medicines and relevant medical conditions, and monitor response and tolerability during treatment.

Switching between treatments

Switching between weight management treatments is a clinical decision, not something to arrange yourself, and it needs a prescriber's involvement for reasons that are practical rather than bureaucratic.

Treatments in this family are not interchangeable unit for unit. They differ in how they are taken, how they build up in the body and how they are started, so moving between them involves planning rather than simply stopping one and starting the other. Timing matters too, particularly around the gap between the last dose of one and the first of another.

If you are considering a change, the useful things to bring are why you want to switch, what your experience has been so far, what side effects you have had and how your weight has responded over time. A change driven by side effects leads to a different conversation from one driven by convenience, and both are legitimate reasons to raise it.

What an assessment involves

An online consultation with UK registered prescribers covers your height and weight, medical history, current medicines, previous weight management attempts and any relevant family history. It exists to establish whether treatment is appropriate and which one fits, rather than to process an order.

Expect to be asked about conditions that change suitability, about previous experience with these medicines, and about what support you have around diet and activity, since the licensed use includes both alongside the medicine. Ongoing review is part of the process rather than an optional extra, because response is monitored over time and treatment is adjusted accordingly.

Medical Disclaimer

This article is for general information only and does not replace personal medical advice. It should not be used to decide on a treatment, to start or stop any medicine, or to delay seeking help. Both treatments discussed are prescription only medicines that require a clinical assessment by a registered prescriber.

Always read the patient information leaflet for the treatment you are given, and speak to a pharmacist, GP or prescriber about your own circumstances and every medicine you take. Regulatory status and availability change, so confirm the current position before acting on anything here. Report suspected side effects through the Yellow Card scheme.